Telomeres and telomerase in Sarcoma disease and therapy.
TERT promoter mutation
sarcoma, osteosarcoma
telomerase
telomere shortening
telomeres
Journal
International journal of medical sciences
ISSN: 1449-1907
Titre abrégé: Int J Med Sci
Pays: Australia
ID NLM: 101213954
Informations de publication
Date de publication:
2024
2024
Historique:
received:
18
04
2024
accepted:
24
07
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
epublish
Résumé
Sarcoma is a rare tumor derived from the mesenchymal tissue and mainly found in children and adolescents. The outcome for patients with sarcoma is relatively poor compared with that for many other solid malignant tumors. Sarcomas have a highly heterogeneous pathogenesis, histopathology and biological behavior. Dysregulated signaling pathways and various gene mutations are frequently observed in sarcomas. The telomere maintenance mechanism (TMM) has recently been considered as a prognostic factor for patients with sarcomas, and alternative lengthening of telomeres (ALT) positivity has been correlated with poor outcomes in patients with several types of sarcomas. Therefore, telomeres and telomerases may be useful targets for treating sarcomas. This review aims to provide an overview of telomere and telomerase biology in sarcomas.
Identifiants
pubmed: 39239547
doi: 10.7150/ijms.97485
pii: ijmsv21p2065
pmc: PMC11373546
doi:
Substances chimiques
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2065-2080Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.